Kazia Therapeutics (NASDAQ:KZIA) Downgraded to Neutral at HC Wainwright

HC Wainwright downgraded shares of Kazia Therapeutics (NASDAQ:KZIAGet Rating) from a buy rating to a neutral rating in a research report report published on Tuesday, The Fly reports.

Kazia Therapeutics Stock Performance

KZIA stock opened at $1.87 on Tuesday. Kazia Therapeutics has a 52 week low of $1.63 and a 52 week high of $12.28. The firm’s 50-day moving average is $4.53 and its two-hundred day moving average is $6.06.

Institutional Trading of Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Envestnet Asset Management Inc. bought a new position in Kazia Therapeutics Limited (NASDAQ:KZIAGet Rating) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 26,412 shares of the company’s stock, valued at approximately $223,000. Envestnet Asset Management Inc. owned approximately 0.20% of Kazia Therapeutics at the end of the most recent reporting period. 3.60% of the stock is currently owned by hedge funds and other institutional investors.

Kazia Therapeutics Company Profile

(Get Rating)

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.

Featured Stories

The Fly logo

Want More Great Investing Ideas?

Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.